CTRI/2015/10/006250
Completed
未知
to study complications of intraviteral injection of bevacizumab
ETHRADHAMA SUPERSPECIALITY EYE HOSPITA0 sites100 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- healthy patients who had given intravitreal bevacizumab for ocular problem
- Sponsor
- ETHRADHAMA SUPERSPECIALITY EYE HOSPITA
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 years
- •Any evidence of ocular neovascularisation, Choroidal neovasular membrane, macular edema due to retinal vein occlusion, diabetic retinopathy
Exclusion Criteria
- •Active external eye infection like conjunctivitis, meibomitis etc.
- •Ischemic maculopathy
- •Presence of any active systemic infections
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
The study for the effect of intravitreous injection of ranibizumab (product name: Lucentis) and subthreshold laser photocoagulation on diabetic macular edemadiabetic macular edemaJPRN-UMIN000017037Jichi Medica University, Saitama Medical Center100
Recruiting
Phase 1
Investigating the effect of mesenchymal stem cell injection on reducing complications in patients with liver cirrhosisReducing complications of liver failure in patients with decompensated liver cirrhosis.Congenital cirrhosis (of liver)P78.81IRCT20140911019125N11Kerman University of Medical Sciences10
Active, not recruiting
Not Applicable
Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem. - DME-TAEUCTR2004-005197-23-DEKlinik und Poliklinik für Augenheilkunde der Universität Regensburg40
Active, not recruiting
Phase 1
A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa.Retinitis Pigmetosa.MedDRA version: 19.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Body processes [G] - Genetic Phenomena [G05]EUCTR2016-002523-28-GBMoorfields Eye Hospital1
Completed
Not Applicable
Retrospective analysis of treatment with intravitreal injections in patients with AMD, DME and RVO in clinical practiceH35.3H34.8Degeneration of macula and posterior poleOther retinal vascular occlusionsDRKS00007999niversitäts-Augenklinik Freiburg1,269